News/Events
News
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.
Flamingo Therapeutics to Present at the BioEquity Europe and Knowledge for Growth Conferences in May 2022
Flamingo Therapeutics, a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer, will present a company ...
Flamingo Therapeutics to Present at BioCapital Europe 2022
Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, ...
Flamingo Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, ...
Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology
Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement ...
Media
Can Cancer Be Treated by Changing Its Cells?
In 2017, Karen Kostroff, a renowned oncology surgeon at Northwell Health in the New York Metropolitan area added a new talking point ...
The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies
Flamingo Therapeutics was born out of a collaboration between three partners in Flanders – VIB, UGent and KU Leuven – and the University of Michigan ...
Leuvense biotechstarter mikt op nieuwe kankertherapieën
Flamingo werd vorig jaar opgericht als spin-off van het Vlaams Instituut voor Biotechnologie (VIB), de KU Leuven en UGent, maar opereerde ...
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect ...